The US Food and Drug Administration’s extensions concerning a Perrigo Company PLC subsidiary’s OTC daily oral contraceptive application didn’t stop with needing additional time to review additional information it requested.
The agency has stretched an advisory panel meeting it will conduct to discuss the application from one day to a...







